Patient management based on risk of death or VTE-related complications at presentation. (°) If available and feasible, extracorporeal membrane oxygenation (ECMO) can be used to support hemodynamics in patients with cardiac arrest. In this case, percutaneous or surgical embolectomy should be preferred over systemic thrombolysis to avoid bleeding. In patients not managed by ECMO, systemic thrombolysis offers the opportunity for rapid reperfusion. (§) catheter-directed therapy to be considered for patients with contraindications for or failure of systemic thrombolysis. (*) Clinical risk assessed by validated models (Pulmonary Embolism Severity Index [PESI], simplified PESI) or based on the combination of vital status and comorbidities. (**) Heparin lead-in stands for initial 5 to 9 days of heparin treatment. (°°) Right ventricle dysfunction (RVD) assessed at echocardiography or computed tomography. (^) Early discharge is defined as occurring within 48 hours from admission. (^^) Treatment should be considered in patients with cancer who have symptoms or are at high risk for VTE. DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin; UFH, unfractionated heparin; iv, intravenous.